Company profile: C4X Discovery
1.1 - Company Overview
Company description
- Provider of NMR-based 3D molecular structure determination to optimize drug design and development, partnering with pharma to generate better, safer products. Offers Conformetrix 4D structural design technology, 4Sight visualizer, PatientSeek for genetic patient stratification, and programs including oral α4β7 integrin inhibitors, IL-17A inhibitors (licensed to Sanofi), and NRF2 activators (licensed to AstraZeneca).
Products and services
- Conformetrix: Engineers 4D structural drug design using experimental-data-driven models to deliver insights into drug molecule shape, conformational behavior, and physicochemical properties for optimising medicine design
- Oral IL-17A Inhibitor Programme: Pre-clinical initiative produces oral IL-17A inhibitors, licensed to Sanofi for further development, enabling orally administered therapeutics targeting IL-17A
- Oral NRF2 activator: Selective programme develops potent oral activators of the NRF2 pathway for inflammatory diseases, licensed to AstraZeneca for progression into partnered development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to C4X Discovery
Zionexa
HQ: United States
Website
- Description: Provider of in-vivo biomarkers developed and commercialized to guide targeted therapies in oncology, aiming to improve patients' pathway and quality of life.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zionexa company profile →
Cartesian Therapeutics
HQ: United States
Website
- Description: Provider of potent, safer cell therapy in and beyond oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cartesian Therapeutics company profile →
Azeria Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule cancer drug development, creating a pipeline of therapies designed to selectively inhibit pioneer factors to aid treatment of breast and prostate cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azeria Therapeutics company profile →
Cellerant Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage cell- and antibody-based immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellerant Therapeutics company profile →
Aulos Bioscience
HQ: United States
Website
- Description: Provider of cancer immuno-oncology therapeutics, including AU-007, a computationally designed human IgG1 monoclonal antibody that selectively binds to the CD25-binding portion of IL-2 to prevent immune suppression, reduce toxic side effects, and enhance immune activation against solid tumors; plus an AI discovery platform by Biolojic Design using machine learning algorithms to design specific, highly selective functional monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aulos Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for C4X Discovery
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to C4X Discovery
2.2 - Growth funds investing in similar companies to C4X Discovery
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for C4X Discovery
4.2 - Public trading comparable groups for C4X Discovery
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →